Global Scans · Pharmaceuticals · Weekly Summary

• [New] Fastest Growing Region - Asia Pacific is set to register the highest CAGR through 2033, fueled by universal health coverage expansion, China's drug access reforms, India's generic drug manufacturing leadership, and rapid e-pharmacy growth across Southeast Asia. Persistence Market Research
• [New] The pharmaceutical sector is projected to grow at a CAGR of 8.2% from 2026 to 2032, driven by rising demand for bioactive compounds derived from pork in nutraceuticals and specialty health products. 6wresearch
• [New] The medical polymers industry was worth USD 20 billion in 2022 and is projected to grow at 8.3% each year until 2032, due to the rising demand for pharmaceutical devices. Global Market Insights Inc.
• [New] Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think of, potentially speeding the race to new cures. MIT Technology Review
• [New] The drug discovery & development segment is anticipated to register the fastest CAGR of 8.43% during 2026-2034. Straits Research
• [New] As personalized medicine and biosimilar manufacturing scale globally, the demand for AI-enabled continuous bioprocessing platforms will intensify, positioning digital biomanufacturing solution providers at the center of a major manufacturing paradigm shift. Persistence Market Research
• [New] The Small Volume Bags segment is projected to register the fastest growth at a CAGR of 6.8% from 2026 to 2033, driven by increasing demand for precise drug delivery and specialty treatments. Data Bridge Market Research
• [New] By 2026, complex drug candidates are routinely evaluated computationally to forecast toxicity and binding before lab work even begins. BuildEZ
• [New] Key Opportunity - Generics represent a compelling margin opportunity, accounting for over 90% of U.S. prescriptions and saving US$ 408 billion annually per AAM data, with India's 10,000+ Jan Aushadhi Kendras and EU biosimilar policy driving further volume growth. Persistence Market Research
• [New] The 118 biologics losing patent protection from 2025 to 2034 represent $234 billion in potential savings, but only 12 have active biosimilar development. DrugPatentWatch - Transform Data into Market Domination
• [New] The first IRA negotiated prices took effect in 2026, and the interaction patterns with biosimilar timing will become clearer as more biologics enter the negotiation process while facing biosimilar competition simultaneously. DrugPatentWatch - Transform Data into Market Domination
• Pyrilutamide from Kintor Pharmaceutical met its Phase 3 primary endpoint in a 666-patient trial in China, with potential commercialization there in 2027. Shapiro Medical Group
• The global pharmaceutical industry is expected to grow from approximately USD 1,627.73 billion in 2025 to USD 1,722.05 billion in 2026, representing a year-over-year growth rate of 5.8%. store.frost.com
• The pharmaceutical corporation sells it for $28,000 a year per patient in the US, even though it could be produced for less than $40. Doctors Without Borders/Medecins Sans Frontieres (MSF)
• New drug development programs could grow by more than 10% in three to five years. Mimir's Well
• As synthetic drugs continue to reshape global drug markets, timely surveillance and public health responses will be essential to reducing harm and protecting communities worldwide. recovered
• Generative AI, combined with other computational tools, could cut drug discovery timelines by as much as 50%. MIT Technology Review
• Drug discovery and materials science are projected to expand at a 31.48% CAGR through 2031, which makes it the fastest-growing application area. Mordor Intelligence

Last updated: 25 August 2026